Mustang Bio Inc
MBIO1.090USD
+0.030+2.83%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.96MMarket Cap
LossP/E TTM
More Details of Mustang Bio Inc Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Mustang Bio Inc Info
Ticker SymbolMBIO
Company nameMustang Bio Inc
IPO dateAug 22, 2017
CEOLitchman (Manuel)
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 22
Address95 Sawyer Rd
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone17816524500
Websitehttps://www.mustangbio.com/
Ticker SymbolMBIO
IPO dateAug 22, 2017
CEOLitchman (Manuel)
Company Executives of Mustang Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.56K
+4.41%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
392.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
379.00
--
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
39.00
--
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.56K
+4.41%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
392.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
379.00
--
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 12
Updated: Fri, Dec 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
3.99%
BlackRock Institutional Trust Company, N.A.
1.31%
Kestra Advisory Services, LLC
1.02%
The Vanguard Group, Inc.
0.90%
Geode Capital Management, L.L.C.
0.41%
Other
92.37%
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
3.99%
BlackRock Institutional Trust Company, N.A.
1.31%
Kestra Advisory Services, LLC
1.02%
The Vanguard Group, Inc.
0.90%
Geode Capital Management, L.L.C.
0.41%
Other
92.37%
Shareholder Types
Shareholders
Proportion
Corporation
3.99%
Investment Advisor
3.40%
Investment Advisor/Hedge Fund
0.41%
Venture Capital
0.29%
Hedge Fund
0.20%
Individual Investor
0.05%
Research Firm
0.04%
Other
91.61%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
66
133.63K
2.09%
-69.17K
2025Q2
79
500.57K
14.17%
+141.50K
2025Q1
99
1.35M
61.40%
+978.22K
2024Q4
107
246.39K
20.57%
+127.81K
2024Q3
122
111.37K
16.10%
+44.38K
2024Q2
137
71.29K
10.74%
+5.47K
2024Q1
164
58.94K
30.95%
-18.94K
2023Q4
172
59.40K
38.79%
+2.99K
2023Q3
181
115.34K
86.47%
+11.94K
2023Q2
197
115.47K
86.60%
+14.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
258.19K
4.04%
+59.33K
+29.84%
Sep 29, 2025
BlackRock Institutional Trust Company, N.A.
1.65K
0.03%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
16.08K
0.25%
+315.00
+2.00%
Jun 30, 2025
SBI Securities Co., Ltd.
502.00
0.01%
+100.00
+24.88%
Jun 30, 2025
Litchman (Manuel)
1.50K
0.02%
-27.00
-1.77%
Apr 24, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Date
Type
Ratio
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Mustang Bio Inc?
The top five shareholders of Mustang Bio Inc are:
Fortress Biotech Inc holds 258.19K shares, accounting for 4.04% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.65K shares, accounting for 0.03% of the total shares.
Geode Capital Management, L.L.C. holds 16.08K shares, accounting for 0.25% of the total shares.
SBI Securities Co., Ltd. holds 502.00 shares, accounting for 0.01% of the total shares.
Litchman (Manuel) holds 1.50K shares, accounting for 0.02% of the total shares.
Fortress Biotech Inc holds 258.19K shares, accounting for 4.04% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.65K shares, accounting for 0.03% of the total shares.
Geode Capital Management, L.L.C. holds 16.08K shares, accounting for 0.25% of the total shares.
SBI Securities Co., Ltd. holds 502.00 shares, accounting for 0.01% of the total shares.
Litchman (Manuel) holds 1.50K shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Mustang Bio Inc?
The top three shareholder types of Mustang Bio Inc are:
Fortress Biotech Inc
BlackRock Institutional Trust Company, N.A.
Kestra Advisory Services, LLC
Fortress Biotech Inc
BlackRock Institutional Trust Company, N.A.
Kestra Advisory Services, LLC
How many institutions hold shares of Mustang Bio Inc (MBIO)?
As of 2025Q3, 66 institutions hold shares of Mustang Bio Inc, with a combined market value of approximately 133.63K, accounting for 2.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.08%.
What is the biggest source of revenue for Mustang Bio Inc?
In --, the -- business generated the highest revenue for Mustang Bio Inc, amounting to -- and accounting for --% of total revenue.
